Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and ...

In the early 1990s, my grandmother’s health and cognitive abilities started to decline rapidly. She showed clear signs of dementia, which was most likely Alzheimer’s disease but never received a ...

They say the mark of intelligence is making the complex simple. By that standard, navigating early commercialization in the pharmaceutical industry is one of the toughest challenges, especially for ...

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...

There are lots of reasons why physicians and patients (and payers) might prefer one drug over another for the treatment of a given disease. Efficacy and safety are paramount, of course, but there are ...

The traditional boundaries between consumer wellness and healthcare are rapidly dissolving. This convergence is creating unprecedented opportunities for innovation, while fundamentally changing how ...